Ken Griffin Werewolf Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$1.71 - $2.95 $1,539 - $2,655
-900 Reduced 56.25%
700 $1,000
Q2 2024

Aug 14, 2024
SELL
$2.34 - $6.75 $1,872 - $5,400
-800 Reduced 33.33%
1,600 $3,000
Q1 2024

May 15, 2024
SELL
$3.92 - $7.91 $5,096 - $10,283
-1,300 Reduced 35.14%
2,400 $15,000
Q4 2023

Feb 14, 2024
BUY
$1.78 - $4.15 $6,586 - $15,355
3,700 New
3,700 $14,000
Q4 2022

Feb 14, 2023
BUY
$1.53 - $4.73 $2,601 - $8,041
1,700 New
1,700 $3,000

Others Institutions Holding HOWL

# of Institutions
69
Shares Held
31.8M
Call Options Held
700
Put Options Held
500
View Full List

About Werewolf Therapeutics, Inc.

HOWL Quotes by TradingView
  • Ticker HOWL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,529,400
  • Market Cap $47M
  • Description
  • Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...
More about HOWL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email